The GeparSixto trial provided evidence that the addition of neoadjuvant carboplatin to a regimen consisting of anthracycline, taxane, and bevacizumab increases pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Whether BRCA1 and BRCA2 germline mutation status affects treatment outcome remains elusive.
T he GeparSixto randomized clinical trial 1 assessed the efficacy of adding neoadjuvant carboplatin to a regimen of paclitaxel, non-pegylated doxorubicin hydrochloride, and targeted therapy for triple-negative breast cancer (TNBC) and ERBB2/HER2 (OMIM 164870)-positive breast cancer. Targeted therapy included lapatinib and trastuzumab for ERBB2/HER2-positive breast cancer and bevacizumab for TNBC. Of the patients with TNBC, 90 of 158 (57%) achieved a pathological complete response (pCR) with carboplatin therapy compared with 67 of 157 patients (42.7%) without carboplatin therapy (P = .015; ypT0/is ypN0 definition). 1 Of the patients with ERBB2/HER2-positive tumors, 72 of 137 (52.6%) achieved a pCR with carboplatin compared with 67 of 136 patients (49.3%) without carboplatin (P = .58; ypT0/is ypN0 definition). 1 Thus, the addition of neoadjuvant carboplatin to the anthracycline and taxane-containing regimen substantially increased pCR rates in patients with TNBC but not in patients with ERBB2/HER2-positive breast cancer. The GeparSixto trial used a nonstandard neoadjuvant chemotherapy regimen that included low-dose doxorubicin and no cyclophosphamide. In the Cancer and Leukemia Group B (CALGB 40603 Alliance) trial, standard neoadjuvant chemotherapy (paclitaxel, dose-dense doxorubicin, and cyclophosphamide) of patients with TNBC revealed elevated pCR rates when carboplatin was added, 2 but an event-free survival benefit was not observed. 3 The triple-negative tumor phenotype accounts for up to 17% of all breast cancers 4 and appears to be associated with a hereditary disease cause. Approximately 70% of breast cancers arising in BRCA1 (OMIM 113705) mutation carriers and up to 23% of breast cancers in BRCA2 (OMIM 600185) carriers are triple negative. 5 In line with these findings, mutational screening of TNBC cases for deleterious germline mutations in BRCA1 and BRCA2 revealed comparatively high mutation frequencies. While germline BRCA1 and BRCA2 mutations were found in 5.3% of all breast cancers according to The Cancer Genome Atlas, 6 a recent study showed that 11.2% of unselected TNBC cases had deleterious mutations in the BRCA1 (8.5%) and BRCA2 (2.7%) genes. Mutations in additional 15 non-BRCA1 and BRCA2 cancer predisposition genes were detected in 3.7% of the patients.
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BRCA1 and BRCA2 are critical genes in the homologous recombination repair of double-stranded DNA breaks. Many of the other genes involved in homologous recombination repair are now recognized to also contribute to hereditary breast cancer risk and/or ovarian cancer risk, including ATM, BRIP1, CHEK2, NBN, PALB2, RAD51C, and RAD51D; limited evidence is available for BARD1, FANCM, MRE11A, and RAD50. [8] [9] [10] [11] [12] Among these genes, only BRCA1, BRCA2, and PALB2 so far have been associated with the TNBC tumor phenotype. 8 Heterozygous germline inactivation of homologous recombination genes may be accompanied by a somatic inactivation of the second allele by mutation, loss of heterozygosity, or promoter methylation and result in a homologous recombination deficiency and limited DNA repair capacities of the tumor cells. 13 This functional role in DNA repair could be exploited in the treatment of homologous recombination-deficient cancers by targeting the tumors with drugs that create DNA damage that is highly reliant on these genes for repair. 14 There is increasing evidence that breast and ovarian cancers arising in BRCA1 and BRCA2 germline mutation carriers are associated with a better response to DNA-damaging treatment regimens. 9, [15] [16] [17] [18] [19] These data prompted us to conduct this prospective-retrospective secondary analysis of the germline mutation status using archived DNA samples and cancer family history of patients with TNBC enrolled in the GeparSixto trial.
Methods

Study Design
The GeparSixto trial cohort, randomization process, clinical procedures, and statistical analyses were described in the initial trial publication. 1 Of the 315 patients with TNBC enrolled between August 1, 2011, and December 31, 2012, in the GeparSixto study, 24 (7.6%) were excluded from this secondary analysis because of unavailable or insufficient amounts of DNA samples ( Figure 1 ). Genomic DNA samples isolated from venous blood samples were derived from the other 291 patients with TNBC (92.4%) and were successfully analyzed for germline mutations. The treatment regimen for these 291 patients is shown in Figure 1 . Data on cancer family history for all 291 patients were available and were considered positive when the inclusion criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for genetic germline testing were fulfilled (eTable 1 in the Supplement). Data analysis took place from November 1, 2015, to December 31, 2015. Ethical approval for this secondary analysis was granted by the ethics committee of the University of Cologne, and written informed consent was obtained from all patients.
Procedures
Genetic analyses were performed at the Center for Familial Breast and Ovarian Cancer in Cologne, Germany, the coordinating entity of the German Consortium for Hereditary Breast and Ovarian Cancer involved in diagnostic BRCA1 and BRCA2 germline testing since 1996. 20 The diagnostic pipeline is certified by the European Molecular Genetics Quality Network. Genomic DNA samples were isolated from venous blood
Key Points
Question Does BRCA1 and BRCA2 germline mutation status predict therapy response in patients with triple-negative breast cancer enrolled in the GeparSixto trial?
Findings In this secondary analysis of a randomized clinical trial of 291 patients with triple-negative breast cancer, patients with BRCA1 and BRCA2 mutations showed superior response rates, without additive effects observed for carboplatin. Patients without BRCA1 and BRCA2 germline mutations benefited from the addition of carboplatin to a regimen of paclitaxel, low-dose doxorubicin, and bevacizumab.
Meaning A less-intense treatment regimen might be considered for BRCA1 and BRCA2 mutation carriers, but further prospective studies are needed to identify the optimal regimen. samples using standard methods. All samples (n = 291) were screened for gross genomic aberrations in the BRCA1 and 
Outcomes
The primary outcome of this biomarker study was the proportion of patients who achieved a pCR and disease-free survival (DFS) after neoadjuvant treatment according to BRCA1 and BRCA2 germline mutation status and family history (eTable 1 in the Supplement). Regarding the pCR rates, the ypT0/is ypN0 definition was used as a primary end point and the more stringent ypT0 ypN0 definition as a secondary end point. 21 Diseasefree survival was defined according to the description by Hudis and colleagues 22 as time in months from randomization until any invasive locoregional (ipsilateral breast, local/regional , both given once a week for 18 weeks, as well as bevacizumab, 15 mg/kg, intravenously every 3 weeks simultaneously with all cycles. Patients who were randomly assigned to receive simultaneous carboplatin received the drug at a dose of 2.0 area under curve (AUC), once every week for 18 weeks. The carboplatin dose was reduced to 1.5 AUC after an interim safety analysis when approximately half of the patients were randomized.
lymph nodes) recurrence of disease, any invasive contralateral breast cancer, any distant recurrence of disease, any secondary malignant neoplasm, or death from any cause, whichever occurs first. Disease progression under therapy was not considered as an event for DFS. Patients without an event (236 of 291 [81%]) were censored at the date of their last contact with the GeparSixto study.
Statistical Methods
The Pearson χ 2 test was used to compare pCR rates between groups. Univariate logistic regressions were performed to estimate odds ratios (ORs) and 95% CIs. Multivariate logistic regressions adjusting for baseline variables (age, tumor stage, nodal status, grading, Ki67 staining level, and BRCA risk according to family history) were performed, including interaction between mutation status and carboplatin treatment. The Kaplan-Meier product-limit method was used to estimate DFS. A Cox proportional hazards model was used to estimate hazard ratios (HRs) and 95% CIs, with a 2-sided Wald P value.
Results pCR Rates in the Study Cohort
Detailed data on cancer family history and blood-derived DNA samples were available from 291 of 315 patients (92.4%) with TNBC enrolled in the GeparSixto trial. Of the 291 patients with TNBC, 100% were women, with a mean (SD) age of 48 (11) years. Compatible with the data on the initially published entire cohort (n = 315), the pCR rate (ypT0/is ypN0 definition) in the carboplatin group was 56.8% (83 of 146 patients) and was 41.4% (60 of 145) in the noncarboplatin group (OR, 1.87; 95% CI, 1.17-2.97; P = .009; Table 1 and Table 2 ), with differences reaching levels of significance in the multivariable analyses (OR, 2.08; 95% CI, 1.19-3.63; P = .01; eTable 4 in the Supplement).
Germline Mutation Spectrum in the Study Cohort
We screened for deleterious germline mutations in BRCA1, BRCA2, and 16 non-BRCA1 and BRCA2 cancer predisposition genes. Besides homologous recombination and other DNA repair genes, cancer predisposition genes not belonging to the DNA repair machinery (CDH1, PTEN, STK11, and TP53), all of which were associated with rare cancer predisposition syndromes, were included. 8 Pathogenic BRCA1 mutations were present in 43 of 291 cases (14.8%), BRCA2 mutations were found in 7 of 291 cases (2.4%), and another 10 cases (3.4%) carried deleterious non-BRCA1 and BRCA2 gene mutations (BARD1
, and XRCC2 [n = 1]). Overall, 50 of 291 patients (17.2%) with TNBC carried germline BRCA1 and BRCA2 alterations, and 10 of 291 patients (3.4%) carried deleterious alterations in other putative cancer predisposition genes (eTable 3 in the Supplement). Because of the small number of patients with deleterious mutations in non-BRCA1 and BRCA2 genes (n = 10) and the unclear association of these genes with the TNBC tumor phenotype, we refrained from calculating pCR rates for this small and heterogeneous subgroup and considered these patients as BRCA1 and BRCA2-negative.
pCR Rates According to BRCA1 and BRCA2 Mutation Status 
DFS Rates According to Treatment and BRCA1 and BRCA2 Mutation Status
With a median follow-up of 35 months, superior DFS rates were observed in the carboplatin group vs the noncarboplatin group (HR, 0.55; 95% CI, 0.32-0.95; P = .03; Figure 2A ). These data were compatible with the early DFS rates described for the entire TNBC cohort (n = 315). 23 Patients with TNBC without pathogenic BRCA1 and BRCA2 alterations showed elevated DFS rates when carboplatin was added to the treatment regimen: without carboplatin, 73.5%; 95% CI, 64.1%-80.8%; with carboplatin, 85.3%; 95% CI 77.0%-90.8% (HR, 0.53; 95% CI, 0.29-0.96; P = .04; Figure 2B ). Regardless of the treatment regimen, the DFS rate was generally high in BRCA1 and BRCA2 mutation carriers, with differences separated by study arm that did not reach levels of significance: without carboplatin, 82.5%; 95% CI, 59.6%-93.1%; with carboplatin, 86.3%; 95% CI, 63.1%-95.4% ( Figure 2B ). We observed a significant correlation of pCR rates with DFS rates (log-rank P < .001) irrespective of the BRCA1 and BRCA2 mutation status (eFigure in the Supplement). A, Disease-free survival by treatment arm. B, Disease-free survival by BRCA1 and BRCA2 mutation status and treatment arm. mt Indicates mutant; PM, paclitaxel and myocet; PMCb, paclitaxel, myocet, and carboplatin; and wt, wild-type.
Discussion
In the noncarboplatin arm, this investigation suggests superior pCR rates in patients with germline BRCA1 and BRCA2 mutations compared with patients without BRCA1 and BRCA2 mutations, with differences translating into clinical benefit when considering the respective DFS rates. This finding may be the result of better treatment response of BRCA1 and BRCA2 mutation carriers to either of the chemotherapeutic agents used in the noncarboplatin arm. The primary mechanism of action of doxorubicin is thought to be via DNA intercalation and stabilization of the topoisomerase IIa/DNA complex, ultimately promoting the formation of single-stranded and doublestranded DNA breaks. 24, 25 Thus, it appears plausible that BRCA1
and BRCA2 mutation carriers achieve higher response rates under therapy with antracyclines because of limited DNA repair capacities of the tumors. On the basis of initial data presented by the randomized Triple Negative Trial, 26 BRCA1 and BRCA2 mutation status is unlikely to be correlated with therapy response to docetaxel. The Triple Negative Trial included patients with metastatic disease, and pretreatment may have changed their responsiveness to chemotherapeutic agents. However, the trial did not suggest that the differences observed between BRCA1 and BRCA2 mutation carriers and noncarriers in the noncarboplatin arm were driven by treatment with taxane. Bevacizumab, a vascular endothelial growth factor inhibitor, has been shown to elevate pCR rates in patients with TNBC (OR, 1.36; 95% CI, 1.11-1.66). 27 Vascular endothelial growth factor expression in tumors of BRCA1 and BRCA2 mutation carriers is demonstrably higher than in sporadic tumors. 28 Concordantly, an investigation of the GeparQuinto trial recently revealed higher pCR rates in response to bevacizumab therapy for BRCA1 and BRCA2 mutation carriers than for noncarriers. However, a superior outcome of survival probability could not be demonstrated. 29 Because the TNBC tumor phenotype is closely associated with hereditary breast cancer, 5 the use of platinum agents has received a new impetus. The cytotoxic actions of platinum drugs are mediated by covalent binding of platinum to DNA, interfering with DNA replication and transcription and ultimately inducing cell death. 30 It seems likely that partially processed cross-links cause replication fork stalling when encountered by the DNA replication machinery during S phase, which may degenerate into double-stranded DNA breaks. 31 Thus, tumor cells with limited DNA repair capacities are hypersensitive against platinum, as demonstrated in preclinical studies. 32 In a recent neoadjuvant trial, platinum-based chemotherapy was shown to be highly effective in BRCA1 germline mutation carriers: a total of 50 of 82 patients (61%) with TNBC experienced a pCR following cisplatin single-agent therapy. 15 The high sensitivity of BRCA1 and BRCA2 mutation carriers to platinbased chemotherapy is in line with data in the metastatic or recurrent locally advanced setting in which carboplatin monotherapy revealed significantly higher response rates in BRCA1 and BRCA2 mutation carriers than in patients without BRCA1 and BRCA2 mutations. 26 In summary, carboplatin therapy has been proven effective in BRCA1 and BRCA2 mutation carriers.
The GeparSixto treatment regimen for TNBC cases included 2 DNA-damaging compounds, doxorubicin and carboplatin, both of which challenge the DNA repair machinery. This finding could explain why, in germline mutation carriers, the addition of carboplatin to the treatment regimen does not further increase pCR or DFS rates above those observed for the combination of paclitaxel, doxorubicin, and bevacizumab. Given that the more intense regimen significantly increases hematological and nonhematological adverse effects in the GeparSixto trial, 1 our findings may have implications for personalized therapy regimens that consider BRCA1 and BRCA2 germline mutation status. Because of the lack of additive effects observed in this study and the finding that elevated pCR rates translate into a clinical benefit, 21 a less intense therapy regimen might be considered for BRCA1 and BRCA2 germline mutation carriers.
Limitations
This study has several limitations. First, the GeparSixto trial was not powered for long-term end points such as DFS and overall survival. Second, there was a small number of patients carrying BRCA1 and BRCA2 (n = 50), especially non-BRCA1 and BRCA2 gene mutations (n = 10). Thus, additional trials are necessary to assess the clinical benefit of a combination use of DNA-damaging compounds, especially in BRCA1 and BRCA2 mutation carriers.
Conclusions
In contrast to the GeparSixto trial, the CALGB 40603 trial revealed that the addition of carboplatin to a standard neoadjuvant chemotherapy (paclitaxel, dose-dense doxorubicin, and cyclophosphamide) did not result in an event-free survival benefit. 2, 3 The GeparSixto trial used a nonstandard neoadjuvant chemotherapy regimen, including low-dose doxorubicin and no cyclophosphamide. Thus, the differences in response rates between the GeparSixto and CALGB 40603 trials might be caused by the different doxorubicin (low dose vs dose dense) and/or cyclophosphamide exposures. It would be interesting to stratify the CALGB 40603 response rates by BRCA1 and BRCA2 mutation status. It appears likely that BRCA1 and BRCA2 mutation carriers show superior response rates following standard neoadjuvant chemotherapy, while patients without BRCA1 and BRCA2 mutations may benefit from the addition of carboplatin. Byrski and colleagues 15, 33 suggested that a chemotherapy regimen with doxorubicin and cyclophosphamide or platinum may result in the highest benefit for BRCA1 germline mutation carriers. This suggestion is based on a limited number of patients, but future trials may evaluate this hypothesis. Under the nonstandard GeparSixto polychemotherapy regimen, however, patients without BRCA1 and BRCA2 germline mutations benefit from the addition of carboplatin while those with BRCA1 and BRCA2 mutations show superior response rates without additive effects observed for carboplatin. Additional prospective studies stratified by BRCA1 and BRCA2 mutation status are needed to elucidate the effect of carboplatin in polychemotherapy regimens. 
